

References

- Alexander, D. D., Mink, P. J., Adami, H.-O., Cole, P., Mandel, J. S., Oken, M. M., & Trichopoulos, D. (2007). Multiple myeloma: A review of the epidemiologic literature. *International Journal of Cancer*, *120*(S12), 40–61. <https://doi.org/10.1002/ijc.22718>
- Amare, K. P., Nikalje Khasnis, S., Hande, P., Lele, H., Wable, N., Kaskar, S., Nikam Gujar, N., Gardi, N., Prabhudesai, A., Todi, K., Waghole, R., & Roy, P. (2022). Cytogenetic abnormalities in multiple myeloma: Incidence, prognostic significance, and geographic heterogeneity in Indian and Western populations. *Cytogenetic and Genome Research*, *162*(10), 529–540. <https://doi.org/10.1159/000529191>
- Andriandi, & Kamal, A. F. (2019). Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. *Annals of Medicine and Surgery*, *41*, 11–15. <https://doi.org/10.1016/j.amsu.2019.03.011>
- Arsham, M. S., Barch, M. J., & Lawce, H. J. (2017). The AGT Cytogenetics Laboratory manual. *The Association of Genetic Technologists*. <https://doi.org/10.1002/9781119061199>
- Bang, S.-M., Kim, Y. R., Cho, H. I., Chi, H. S., Seo, E.-J., Park, C. J., Yoo, S. J., Kim, H. C., Chun, H. G., Min, H. C., Oh, B. R., Kim, T. Y., Lee, J. H., & Lee, D. S. (2006). Identification of 13Q deletion, trisomy 1Q, and igh rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. *Cancer Genetics and Cytogenetics*, *168*(2), 124–132. <https://doi.org/10.1016/j.cancergencyto.2006.02.015>
- Bergsagel, P. L., & Kuehl, W. M. (2001). Chromosome translocations in multiple myeloma. *Oncogene*, *20*(40), 5611–5622. <https://doi.org/10.1038/sj.onc.1204641>
- Bianchi, G., & Munshi, N. C. (2015). Pathogenesis beyond the cancer clone(s) in multiple myeloma. *Blood*, *125*(20), 3049–3058. <https://doi.org/10.1182/blood-2014-11-568881>

- Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., Facon, T., Dumontet, C., Barlogie, B., Arhini, A., Rustad, E. H., Maura, F., Landgren, O., Zhan, F., van Rhee, F., ... Walker, B. A. (2021). The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. *Nature Communications*, *12*(1). <https://doi.org/10.1038/s41467-020-20524-2>
- Bridge, J. A. (2008). Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms. *Journal of Orthopaedic Science*, *13*(3), 273–282. <https://doi.org/10.1007/s00776-007-1215-1>
- Chesi, M., & Bergsagel, P. L. (2015). Advances in the pathogenesis and diagnosis of multiple myeloma. *International Journal of Laboratory Hematology*, *37*(S1), 108–114. <https://doi.org/10.1111/ijlh.12360>
- Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., ... & Mey, U. (2021). Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, *32*(3), 309-322. <https://doi.org/10.1016/j.annonc.2020.11.014>
- Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2018). Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. *International Journal of Cancer*, *144*(8), 1941–1953. <https://doi.org/10.1002/ijc.31937>
- Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020). Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. *Cells*, *9*(2), 287. <https://doi.org/10.3390/cells9020287>

- Gao, X., Li, C., Zhang, R., Yang, R., Qu, X., Qiu, H., Xu, J., Lu, H., Li, J., & Chen, L. (2011). Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. *Medical Oncology*, 29(3), 2200–2206. <https://doi.org/10.1007/s12032-011-9988-7>
- GLOBOCAN. (2020). *Indonesia - International Agency for Research on Cancer*. International Agency for Research on Cancer. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
- Govindasamy, P., Pandurangan, P., Tarigopula, A., Mani, R., & R Samuel, C. (2019). Cytogenetic abnormalities in multiple myeloma patients at a tertiary healthcare center in India. *Asian Pacific Journal of Cancer Prevention*, 20(1), 235–241. <https://doi.org/10.31557/apjcp.2019.20.1.235>
- Gu, J., Smith, J. L., & Dowling, P. K. (2016). Fluorescence in situ hybridization probe validation for clinical use. *Methods in Molecular Biology*, 101–118. https://doi.org/10.1007/978-1-4939-6703-2_10
- Hameed, A., Ali, J., Munawar, K., Arshad, F., Badar, F., & Siddiqui, N. (2018). Characteristics and outcomes of patients with multiple myeloma : Data from a developing country. *Medical Journal of The Islamic Republic of Iran*, 32(1), 1–5. <https://doi.org/10.14196/mjiri.32.1>
- Hartmann, L., Biggerstaff, J. S., Chapman, D. B., Scott, J. M., Johnson, K. R., Ghirardelli, K. M., Fritschle, W. K., Martinez, D. L., Bennington, R. K., de Baca, M. E., Wells, D. A., Loken, M. R., & Zehentner, B. K. (2011). Detection of genomic abnormalities in multiple myeloma. *American Journal of Clinical Pathology*, 136(5), 712–720. <https://doi.org/10.1309/ajcpf7nflw8uajep>
- Herrero, A., Rojas, E., Misiewicz-Krzeminska, I., Krzeminski, P., & Gutiérrez, N. (2016). Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma. *International Journal of Molecular Sciences*, 17(12), 2003. <https://doi.org/10.3390/ijms17122003>

- Huang, S.-Y., Yao, M., Tang, J.-L., Tsay, W., Lee, F.-Y., Liu, M.-C., Wang, C.-H., Chen, Y.-C., Shen, M.-C., & Tien, H.-F. (2005). Clinical significance of cytogenetics and Interphase Fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. *Annals of Oncology*, *16*(9), 1530–1538. <https://doi.org/10.1093/annonc/mdi273>
- Hurt, E. M., Wiestner, A., Rosenwald, A., Shaffer, A. L., Campo, E., Grogan, T., Bergsagel, P. L., Kuehl, W. M., & Staudt, L. M. (2004). Overexpression of C-MAF is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. *Cancer Cell*, *5*(2), 191–199. [https://doi.org/10.1016/s1535-6108\(04\)00019-4](https://doi.org/10.1016/s1535-6108(04)00019-4)
- Jiang, Q., Mao, H., He, G., & Mao, X. (2022). Targeting the oncogenic transcription factor C-MAF for the treatment of multiple myeloma. *Cancer Letters*, *543*, 215791. <https://doi.org/10.1016/j.canlet.2022.215791>
- Jiang, Y., Zhang, C., Lu, L., Wang, X., Liu, H., Jiang, Y., Hong, L., Chen, Y., Huang, H., & Guo, D. (2022). The prognostic role of Cyclin D1 in multiple myeloma: A systematic review and meta-analysis. *Technology in Cancer Research & Treatment*, *21*, 153303382110652. <https://doi.org/10.1177/15330338211065252>
- Kim, K., Lee, J. H., Kim, J. S., Min, C. K., Yoon, S. S., Shimizu, K., Chou, T., Kosugi, H., Suzuki, K., Chen, W., Hou, J., Lu, J., Huang, X.-J., Huang, S.-Y., Chng, W. J., Tan, D., Teoh, G., Chim, C. S., Nawarawong, W., ... Durie, B. G. (2014). Clinical profiles of multiple myeloma in Asia-an Asian myeloma network study. *American Journal of Hematology*, *89*(7), 751–756. <https://doi.org/10.1002/ajh.23731>
- Klimienė, I., Radzevičius, M., Matuzevičienė, R., Sinkevič-Belliot, K., Kučinskienė, Z. A., & Pečeliūnas, V. (2020). Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.

- International Journal of Laboratory Hematology*, 43(3), 403–408.
<https://doi.org/10.1111/ijlh.13387>
- Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017). Multiple myeloma. *Nature Reviews Disease Primers*, 3(1).
<https://doi.org/10.1038/nrdp.2017.46>
- Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. *New England Journal of Medicine*, 378(3), 241–249. <https://doi.org/10.1056/nejmoa1709974>
- Li, C., Wendlandt, E. B., Darbro, B., Xu, H., Thomas, G. S., Tricot, G., Chen, F., Shaughnessy, J. D., & Zhan, F. (2021). Genetic analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression. *Cancers*, 13(3), 517.
<https://doi.org/10.3390/cancers13030517>
- Li, S., Lim, H.-H., Woo, K.-S., Kim, S.-H., & Han, J.-Y. (2016). A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: A single center study in Korea. *Blood Research*, 51(2), 122. <https://doi.org/10.5045/br.2016.51.2.122>
- Liehr, T. (2023). *Cytogenetics and molecular cytogenetics*. CRC Press, Taylor & Francis Group.
- Lim, A. S. T., Lim, T. H., See, K. H. S., Ng, Y. J., Tan, Y. M., Choo, N. S. L., ... & Tan, D. C. L. (2013). Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore. *Chinese Medical Journal*, 126(10), 1872-1877.
<https://doi.org/10.3760/cma.j.issn.0366-6999.20123344>
- Lode, L., Eveillard, M., Trichet, V., Soussi, T., Wuilleme, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traulle, C., Guilhot, F., Caillot, D., Marit, G., Mathiot, C., Facon, T., Attal, M., Harousseau, J.-L., Moreau, P., Minvielle, S., & Avet-Loiseau, H. (2010). Mutations in TP53 are

- exclusively associated with DEL(17P) in multiple myeloma. *Haematologica*, 95(11), 1973–1976.
<https://doi.org/10.3324/haematol.2010.023697>
- Lu, G., Muddasani, R., Orlowski, R. Z., Abruzzo, L. V., Qazilbash, M. H., You, M. J., Wang, Y., Zhao, M., Chen, S., Glitza, I. C., & Medeiros, L. J. (2013). Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. *Archives of Pathology & Laboratory Medicine*, 137(5), 625–631. <https://doi.org/10.5858/arpa.2012-0209-0a>
- Ludwig, H., Novis Durie, S., Meckl, A., Hinke, A., & Durie, B. (2020). Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. *The Oncologist*, 25(9).
<https://doi.org/10.1634/theoncologist.2020-0141>
- López-Corral, L., Gutiérrez, N. C., Vidriales, M. B., Mateos, M. V., Rasillo, A., García-Sanz, R., Paiva, B., & San Miguel, J. F. (2011). The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. *Clinical Cancer Research*, 17(7), 1692–1700. <https://doi.org/10.1158/1078-0432.ccr-10-1066>
- Manier, S., Salem, K., Glavey, S. V., Roccaro, A. M., & Ghobrial, I. M. (2016). Genomic aberrations in multiple myeloma. *Plasma Cell Dyscrasias*, 23–34.
https://doi.org/10.1007/978-3-319-40320-5_3
- National Comprehensive Cancer Network. (2023). *NCCN Guidelines Version 1.2024 Multiple Myeloma*. NCCN Clinical Practice Guidelines in Oncology.
<https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManagerGuid?FileManagerGuidId=e3395880-f737-42f6-bb45-528c2ec35cdc>

- OGT. (2021). *Haematology fish probes for multiple myeloma*. CytoCell. <https://www.ogt.com/media/11of12sf/haematology-fish-probes-for-multiple-myeloma.pdf>
- Oliva, S., Genuardi, E., Belotti, A., Frascione, P. M., Galli, M., Capra, A., Offidani, M., Vozella, F., Zambello, R., Auclair, D., Kirsch, I., Ruggeri, M., Jacob, A., Ledda, A., Corradini, P., Gilestro, M., Zamagni, E., Musto, P., Boccadoro, M., & Gay, F. (2020). Multiparameter flow cytometry (MFC) and Next Generation Sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the forte trial in newly diagnosed multiple myeloma (mm). *Journal of Clinical Oncology*, 38(15_suppl), 8533–8533. https://doi.org/10.1200/jco.2020.38.15_suppl.8533
- Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., Bringhen, S., Gay, F., Attal, M., Passera, R., Spencer, A., Offidani, M., Kumar, S., Musto, P., Lonial, S., ... Moreau, P. (2015). Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. *Journal of Clinical Oncology*, 33(26), 2863–2869. <https://doi.org/10.1200/jco.2015.61.2267>
- Phornsarayuth, P., KorKiasakul, V., Puavilai, T., Boonyawat, K., Niparuck, P., Chuncharunee, S., Chareonsirisuthigul, T., & Rerkamnuaychoke, B. (2016). Molecular cytogenetic aberrations in Thai patients with multiple myeloma. *Genomics and Genetics*, 9(1).
- Pozdnyakova, O., Crowley-Larsen, P., Zota, V., Wang, S. A., & Miron, P. M. (2009). Interphase fish in plasma cell dyscrasia: Increase in abnormality detection with plasma cell enrichment. *Cancer Genetics and Cytogenetics*, 189(2), 112–117. <https://doi.org/10.1016/j.cancergencyto.2008.11.007>
- Rajan, A. M., & Rajkumar, S. V. (2015). Interpretation of cytogenetic results in multiple myeloma for clinical practice. *Blood Cancer Journal*, 5(10). <https://doi.org/10.1038/bcj.2015.92>

- Rajkumar, S. V. (2022). Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, 97(8), 1086–1107. <https://doi.org/10.1002/ajh.26590>
- Rasche, L., Kortüm, K., Raab, M., & Weinhold, N. (2019). The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. *International Journal of Molecular Sciences*, 20(5), 1248. <https://doi.org/10.3390/ijms20051248>
- Sayuti, N. A., Andayani, T. M., Endarti, D., & Taroeno-Hariadi, K. W. (2019). Health- related quality of life for multiple myeloma patients with bone metastases in Indonesia: A cross-sectional study. *Asian Pacific Journal of Cancer Prevention*, 20(10), 3161–3166. <https://doi.org/10.31557/apjcp.2019.20.10.3161>
- Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022). Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.973836>
- Sutandyo, N., Firna, E., Agustina, J., Prayogo, N., & Widjaja, L. (2015). Clinicopathology profile and bone involvement of multiple myeloma patients in Dharmais National Cancer Hospital, Indonesia. *Asian Pacific Journal of Cancer Prevention*, 16(15), 6261–6265. <https://doi.org/10.7314/apjcp.2015.16.15.6261>
- Tadjoedin, H., Reksodiputro, A. H., & Toruan, T. (2011). Multiple Myeloma in Indonesia. *Indonesian Journal of Cancer*, 5(2). <https://doi.org/10.33371/ijoc.v5i2.134>
- Vízkeleti, L., Ecsedi, S., Rákossy, Z., Orosz, A., Lázár, V., Emri, G., Koroknai, V., Kiss, T., Ádány, R., & Balázs, M. (2012). The role of CCND1 alterations during the progression of cutaneous malignant melanoma. *Tumor Biology*, 33(6), 2189–2199. <https://doi.org/10.1007/s13277-012-0480-6>

- Wiedmeier-Nutor, J. E., & Bergsagel, P. L. (2022). Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. *Life*, *12*(6), 812. <https://doi.org/10.3390/life12060812>
- Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., & Rao, P. N. (2007a). Guidance for fluorescence in situ hybridization testing in hematologic disorders. *The Journal of Molecular Diagnostics*, *9*(2), 134–143. <https://doi.org/10.2353/jmoldx.2007.060128>
- Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., & Rao, P. N. (2007b). Guidance for fluorescence in situ hybridization testing in hematologic disorders. *The Journal of Molecular Diagnostics*, *9*(2), 134–143. <https://doi.org/10.2353/jmoldx.2007.060128>
- Xiong, W., Wu, X., Starnes, S., Johnson, S. K., Haessler, J., Wang, S., Chen, L., Barlogie, B., Shaughnessy, J. D., & Zhan, F. (2008). An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. *Blood*, *112*(10), 4235–4246. <https://doi.org/10.1182/blood-2007-10-119123>